Class summary at a glance.

Every drug in the Complement Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $405.0Mcombined across class
Total Rx claims: 10K1K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Eculizumab

Brand: SOLIRIS · 6K Part D claims (CY24) · 714 beneficiaries · First FDA approval: 2007-04-02

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $273.2M

Class share

67%

of class CY24 spend

View profile →

Zilucoplan

Brand: ZILBRYSQ · 2K Part D claims (CY24) · 483 beneficiaries · First FDA approval: 2024-01-03

Brand-only (no generics) 80 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $90.6M

Class share

22%

of class CY24 spend

View profile →

Pegcetacoplan

Brand: Empaveli · 1K Part D claims (CY24) · 125 beneficiaries · First FDA approval: 2021-05-14

Brand-only (no generics) 28 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $41.1M

Class share

10%

of class CY24 spend

View profile →

Eculizumab-Aagh

Brand: EPYSQLI · — Part D claims (CY24) · First FDA approval: 2025-04-07

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Eculizumab-Aeeb

Brand: BKEMV · — Part D claims (CY24) · First FDA approval: 2025-03-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Pozelimab

Brand: VEOPOZ · — Part D claims (CY24) · First FDA approval: 2023-08-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ravulizumab

Brand: Ultomiris · — Part D claims (CY24) · First FDA approval: 2018-12-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.